-
Jiangsu Recbio Shoots To Become Hong Kong's First HPV Vaccine Stock
Thursday, January 27, 2022 - 11:15am | 1116Read More...Key takeaways: Jiangsu Recbio has filed a second IPO application to list in Hong Kong, hoping to become the first HPV vaccine maker in the market The company was valued at around 9 billion yuan after its latest funding round By Molly Wen What started as a chance to participate in trials for an...
-
Novan CEO Talks About The Company's Future: 'Our Focus Is Put On SB204'
Friday, December 9, 2016 - 7:39pm | 617Read More...Benzinga recently had the chance to chat with Novan Inc (NASDAQ: NOVN)’s CEO Nathan Stasko. In a previous article, he talked about the company’s HPV drug; in this article, we’ll look into his prospects for the business, potential catalysts and financing. Capital Issues When...
-
Novan CEO Discusses Its HPV Drug And Clinical Trial Results
Friday, December 9, 2016 - 4:41pm | 585Read More...Novan Inc (NASDAQ: NOVN) is a small-cap late-stage pharmaceutical company focused on the treatment of acne vulgaris, external genital and perianal warts, fungal infections of the skin and nails, and inflammatory skin diseases. The stock has gained almost 58 percent since its late-September IPO,...
